Investigational immunomodulatory drugs for enhancement of triple negative breast cancer (TNBC) immunotherapy: early phase development

References

• Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med. 2010;363(20):1938–1948.
   PubMed Web of Science ®Google Scholar
• Cardoso F, Paluch-Shimon S, Senkus E, et al. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Ann Oncol. 2020;31(12):1623–1649.
   PubMed Web of Science ®Google Scholar
• Tarantino P, Morganti S, Curigliano G. Biologic therapy for advanced breast cancer: recent advances and future directions. Expert Opin Biol Ther. 2020;20(9):1009–1024.
   PubMed Web of Science ®Google Scholar
• Shimelis H, LaDuca H, Hu C, et al. Triple-negative breast cancer risk genes identified by multigene hereditary cancer panel testing. JNCI J Natl Cancer Inst. 2018;110(8):855–862.
   Web of Science ®Google Scholar
• Cortesi L, Rugo HS, Jackisch C. An overview of PARP inhibitors for the treatment of breast cancer. Target Oncol. 2021;16(3):255–282.
   PubMed Web of Science ®Google Scholar
• Schmid P, Adams S, Rugo HS, et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med. 2018;379(22):2108–2121.
   PubMed Web of Science ®Google Scholar
• Cortes J, Cescon DW, Rugo HS, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet. 2020;396(10265):1817–1828.
   PubMed Web of Science ®Google Scholar
• Rugo HS, Loi S, Adams S, et al. Performance of PD-L1 immunohistochemistry (IHC) assays in unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC): post-hoc analysis of IMpassion130. Ann Oncol. 2019;30:v858–v859.
   PubMed Web of Science ®Google Scholar
• Sharma P, Siddiqui BA, Anandhan S, et al. The next decade of immune checkpoint therapy. Cancer Discov. 2021;11(4):838–857.
   PubMed Web of Science ®Google Scholar
• Schmid P, Rugo HS, Adams S, et al. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2020;21(1):44–59.
   PubMed Web of Science ®Google Scholar
• Xiao Y, Ma D, Zhao S, et al. Multi-omics profiling reveals distinct microenvironment characterization and suggests immune escape mechanisms of triple-negative breast cancer. Clin Cancer Res. 2019;25(16):5002–5014.
   PubMed Web of Science ®Google Scholar
• Savas P, Salgado R, Denkert C, et al. Clinical relevance of host immunity in breast cancer: from TILs to the clinic. Nat Rev Clin Oncol. 2016;13(4):228–241.
   PubMed Web of Science ®Google Scholar
• Disis ML, Stanton SE. Triple-negative breast cancer: immune modulation as the new treatment paradigm. Am Soc Clin Oncol Educ. 2015;(35):B e25–e30. DOI:https://doi.org/10.14694/EdBook_AM.2015.35.e25.
   Google Scholar
• Narang P, Chen M, Sharma AA, et al. The neoepitope landscape of breast cancer: implications for immunotherapy. BMC Cancer. 2019;19(1):200.
   PubMed Web of Science ®Google Scholar
• Stanton SE, Adams S, Disis ML. Variation in the incidence and magnitude of tumor-infiltrating lymphocytes in breast cancer subtypes. JAMA Oncol. 2016;2(10):1354.
   PubMed Web of Science ®Google Scholar
• Denkert C, von Minckwitz G, Darb-Esfahani S, et al. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. Lancet Oncol. 2018;19(1):40–50.
   PubMed Web of Science ®Google Scholar
• Dieci MV, Radosevic-Robin N, Fineberg S, et al. Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: a report of the international immuno-oncology biomarker working group on bre. Semin Cancer Biol. 2018;52:16–25.
   PubMed Web of Science ®Google Scholar
• Salgado R, Denkert C, Demaria S, et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann Oncol. 2015;26(2):259–271.
   PubMed Web of Science ®Google Scholar
• Shen M, Wang J, Ren X. New insights into tumor-infiltrating B lymphocytes in breast cancer: clinical impacts and regulatory mechanisms. Front Immunol. 2018;9. DOI:https://doi.org/10.3389/fimmu.2018.00470
   Google Scholar
• Mehta AK, Cheney EM, Hartl CA, et al. Targeting immunosuppressive macrophages overcomes PARP inhibitor resistance in BRCA1-associated triple-negative breast cancer. Nat Cancer. 2021;2(1):66–82.
   PubMedGoogle Scholar
• Wellenstein MD, Coffelt SB, Duits DEM, et al. Loss of p53 triggers WNT-dependent systemic inflammation to drive breast cancer metastasis. Nature. 2019;572(7770):538–542.
   PubMed Web of Science ®Google Scholar
• Bianchini G, Balko JM, Mayer IA, et al. Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Nat Rev Clin Oncol. 2016;13(11):674–690.
   PubMed Web of Science ®Google Scholar
• Cassetta L, Fragkogianni S, Sims AH, et al. Human tumor-associated macrophage and monocyte transcriptional landscapes reveal cancer-specific reprogramming, biomarkers, and therapeutic targets. Cancer Cell. 2019;35(4):588–602.e10.
   PubMed Web of Science ®Google Scholar
• Guo T, Li W, Cai X. Applications of single-cell omics to dissect tumor microenvironment. Front Genet. 2020;11. DOI: https://doi.org/10.3389/fgene.2020.548719
   Google Scholar
• Lee J, Hyeon DY, Hwang D. Single-cell multiomics: technologies and data analysis methods. Exp Mol Med. 2020;52(9):1428–1442.
   PubMed Web of Science ®Google Scholar
• Samstein RM, Krishna C, Ma X, et al. Mutations in BRCA1 and BRCA2 differentially affect the tumor microenvironment and response to checkpoint blockade immunotherapy. Nat Cancer. 2020;1(12):1188–1203.
   PubMedGoogle Scholar
• Emens LA, Molinero L, Loi S, et al. Atezolizumab and nab -paclitaxel in advanced triple-negative breast cancer: biomarker evaluation of the IMpassion130 study. JNCI J Natl Cancer Inst. 2021;113(8):1005–1016.
   Web of Science ®Google Scholar
• Greenup R, Buchanan A, Lorizio W, et al. Prevalence of BRCA mutations among women with triple-negative breast cancer (TNBC) in a genetic counseling Cohort. Ann Surg Oncol. 2013;20(10):3254–3258.
   PubMed Web of Science ®Google Scholar
• Guney Eskiler G, Cecener G, Egeli U, et al. Triple negative breast cancer: new therapeutic approaches and BRCA status. APMIS. 2018;126(5):371–379.
   PubMed Web of Science ®Google Scholar
• Incorvaia L, Fanale D, Bono M, et al. BRCA1/2 pathogenic variants in triple-negative versus luminal-like breast cancers: genotype–phenotype correlation in a cohort of 531 patients. Ther Adv Med Oncol. 2020;12:175883592097532.
   Web of Science ®Google Scholar
• Pogoda K, Niwińska A, Sarnowska E, et al. Effects of BRCA germline mutations on triple-negative breast cancer prognosis. J Oncol. 2020;8545643:2020.
   Google Scholar
• Hollern DP, Xu N, Thennavan A, et al. B cells and T follicular helper cells mediate response to checkpoint inhibitors in high mutation burden mouse models of breast cancer. Cell. 2019;179(5):1191–1206.e21.
   PubMed Web of Science ®Google Scholar
• Savas P, Virassamy B, Ye C, et al. Single-cell profiling of breast cancer T cells reveals a tissue-resident memory subset associated with improved prognosis. Nat Med. 2018;24(7):986–993.
   PubMed Web of Science ®Google Scholar
• Lehmann BD, Pietenpol JA. Identification and use of biomarkers in treatment strategies for triple-negative breast cancer subtypes. J Pathol. 2014;232(2):142–150.
   PubMed Web of Science ®Google Scholar
• Narayan P, Wahby S, Gao JJ, et al. FDA approval summary: atezolizumab plus paclitaxel protein-bound for the treatment of patients with advanced or metastatic TNBC whose tumors express PD-L1. Clin Cancer Res. 2020;26(10):2284–2289.
   PubMed Web of Science ®Google Scholar
• Kwapisz D. Pembrolizumab and atezolizumab in triple-negative breast cancer. Cancer Immunol Immunother. 2021;70(3):607–617.
   PubMed Web of Science ®Google Scholar
• Adams S, Gatti-Mays ME, Kalinsky K, et al. Current landscape of immunotherapy in breast cancer. JAMA Oncol. 2019;5(8):1205.
   PubMed Web of Science ®Google Scholar
• Emens LA. Breast cancer immunotherapy: facts and hopes. Clin Cancer Res. 2018;24(3):511–520.
   PubMed Web of Science ®Google Scholar
• Winer EP, Lipatov O, Im S-A, et al. Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22(4):499–511.
   PubMed Web of Science ®Google Scholar
• Tarantino P, Curigliano G. Defining the immunogram of breast cancer: a focus on clinical trials. Expert Opin Biol Ther. 2019;19(5):383–385.
   PubMed Web of Science ®Google Scholar
• national comprehensive cancer network clinical practice guidelines in oncology - breast cancer [internet]; [ cited 2019 Sep 03]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/breast_blocks.pdf
   Google Scholar
• Miles DW, Gligorov J, André F, et al. LBA15 Primary results from IMpassion131, a double-blind placebo-controlled randomised phase III trial of first-line paclitaxel (PAC) ± atezolizumab (atezo) for unresectable locally advanced/metastatic triple-negative breast cancer (mTNBC). Ann Oncol. 2020;31:S1147–S1148.
   Web of Science ®Google Scholar
• Tarantino P, Gandini S, Trapani D, et al. Immunotherapy addition to neoadjuvant chemotherapy for early triple negative breast cancer: a systematic review and meta-analysis of randomized clinical trials. Crit Rev Oncol Hematol. 2021;159:103223.
   PubMed Web of Science ®Google Scholar
• Schmid P, Cortes J, Pusztai L, et al. Pembrolizumab for early triple-negative breast cancer. N Engl J Med. 2020;382(9):810–821.
   PubMed Web of Science ®Google Scholar
• Mittendorf EA, Zhang H, Barrios CH, et al. Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial. Lancet. 2020;396(10257):1090–1100.
   PubMed Web of Science ®Google Scholar
• Loibl S, Schneeweiss A, Huober J. et al. Durvalumab improves long-term outcome in TNBC: results from the phase II randomized GeparNUEVO study investigating neoadjuvant durvalumab in addition to an anthracycline/taxane based neoadjuvant chemotherapy in early triple-negative breast cancer. J Clin Oncol Abstract. 2021;5;506.
   Google Scholar
• Nanda R, Liu MC, Yau C, et al. Effect of pembrolizumab plus neoadjuvant chemotherapy on pathologic complete response in women with early-stage breast cancer. JAMA Oncol. 2020;6:676.
   PubMed Web of Science ®Google Scholar
• Merck announces phase 3 KEYNOTE-522 trial met dual primary endpoint of EFS in patients with high-risk early-stage TNBC; [cited May 26, 2021]. [Internet]Available from: https://www.merck.com/news/merck-announces-phase-3-keynote-522-trial-met-dual-primary-endpoint-of-event-free-survival-efs-in-patients-with-high-risk-early-stage-triple-negative-breast-cancer-tnbc
   Google Scholar
• Haanen JBAG, Carbonnel F, Robert C, et al. Management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28:iv119–iv142.
   PubMed Web of Science ®Google Scholar
• Quagliariello V, Passariello M, Rea D, et al. Evidences of CTLA-4 and PD-1 blocking agents-induced cardiotoxicity in cellular and preclinical models. J Pers Med. 2020;10(4):179.
   Web of Science ®Google Scholar
• Quagliariello V, Passariello M, Coppola C, et al. Cardiotoxicity and pro-inflammatory effects of the immune checkpoint inhibitor Pembrolizumab associated to Trastuzumab. Int J Cardiol. 2019;292:171–179.
   PubMed Web of Science ®Google Scholar
• Quagliariello V, De Laurentiis M, Cocco S, et al. NLRP3 as putative marker of ipilimumab-induced cardiotoxicity in the presence of hyperglycemia in estrogen-responsive and triple-negative breast cancer cells. Int J Mol Sci. 2020;21(20):7802.
   Web of Science ®Google Scholar
• Emens LA, Cruz C, Eder JP, et al. Long-term clinical outcomes and biomarker analyses of atezolizumab therapy for patients with metastatic triple-negative breast cancer. JAMA Oncol. 2019;5:74-82.
   Web of Science ®Google Scholar
• Adams S, Schmid P, Rugo HS, et al. Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study. Ann Oncol. 2019;30(3):397–404.
   PubMed Web of Science ®Google Scholar
• Lyons TG. Targeted therapies for triple-negative breast cancer. Curr Treat Options Oncol. 2019;20(11):82.
   Web of Science ®Google Scholar
• Salgado R, Bellizzi AM, Rimm D, et al. How current assay approval policies are leading to unintended imprecision medicine. Lancet Oncol. 2020;21(11):1399–1401.
   PubMed Web of Science ®Google Scholar
• Loibl S, Untch M, Burchardi N, et al. A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study. Ann Oncol. 2019;30(8):1279–1288.
   PubMed Web of Science ®Google Scholar
• Gianni L, Huang C-S, Egle D, et al. Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple negative, early high-risk and locally advanced breast cancer. NeoTRIPaPDL1 Michelangelo randomized study [Internet]. Sabcs, 2019 [cited 2021 Jul 30]. Available from: https://www.abstractsonline.com/pp8/#!/7946/presentation/1911
   Google Scholar
• Karn T, Denkert C, Weber KE, et al. Tumor mutational burden and immune infiltration as independent predictors of response to neoadjuvant immune checkpoint inhibition in early TNBC in GeparNuevo. Ann Oncol. 2020;31(9):1216–1222.
   PubMed Web of Science ®Google Scholar
• Badalamenti G, Fanale D, Incorvaia L, et al. Role of tumor-infiltrating lymphocytes in patients with solid tumors: can a drop dig a stone? Cell Immunol. 2019;343:103753.
   PubMed Web of Science ®Google Scholar
• Luen SJ, Savas P, Fox SB, et al. Tumour-infiltrating lymphocytes and the emerging role of immunotherapy in breast cancer. Pathology. 2017;49(2):141–155.
   PubMed Web of Science ®Google Scholar
• Loi S, Drubay D, Adams S, et al. Tumor-infiltrating lymphocytes and prognosis: a pooled individual patient analysis of early-stage triple-negative breast cancers. J Clin Oncol. 2019;37(7):559–569.
   PubMed Web of Science ®Google Scholar
• Park JH, Jonas SF, Bataillon G, et al. Prognostic value of tumor-infiltrating lymphocytes in patients with early-stage triple-negative breast cancers (TNBC) who did not receive adjuvant chemotherapy. Ann Oncol. 2019;30(12):1941–1949.
   PubMed Web of Science ®Google Scholar
• Burstein HJ, Curigliano G, Loibl S, et al. Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen international consensus guidelines for the primary therapy of early breast cancer 2019. Ann Oncol. 2019;30:1541–1557.
   PubMed Web of Science ®Google Scholar
• Loi S. The ESMO clinical practise guidelines for early breast cancer: diagnosis, treatment and follow-up: on the winding road to personalized medicine. Ann Oncol. 2019;30(8):1183–1184.
   PubMed Web of Science ®Google Scholar
• Dieci MV, Criscitiello C, Goubar A, et al. Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study. Ann Oncol. 2014;25(3):611–618.
   PubMed Web of Science ®Google Scholar
• Luen SL, Salgado R, Loi S. Residual disease and immune infiltration as a new surrogate endpoint for TNBC post neoadjuvant chemotherapy. Oncotarget. 2019;10(45):4612–4614.
   PubMedGoogle Scholar
• Prowell TM, Beaver JA, Pazdur R. Residual disease after neoadjuvant therapy — developing drugs for high-risk early breast cancer. N Engl J Med. 2019;380(7):612–615.
   PubMed Web of Science ®Google Scholar
• Szekely B, Bossuyt V, Li X, et al. Immunological differences between primary and metastatic breast cancer. Ann Oncol. 2018;29(11):2232–2239.
   PubMed Web of Science ®Google Scholar
• Garrido-Castro AC, Spurr LF, Hughes ME, et al. Genomic characterization of de novo metastatic breast cancer. Clin Cancer Res. 2021;27(4):1105–1118.
   PubMed Web of Science ®Google Scholar
• Alva AS, Mangat PK, Garrett-Mayer E, et al. Pembrolizumab in patients with metastatic breast cancer with high tumor mutational burden: results from the targeted agent and profiling utilization registry (TAPUR) study. J Clin Oncol. 2021 Aug 1;39(22):2443-2451
   Web of Science ®Google Scholar
• O’Meara TA, Tolaney SM. Tumor mutational burden as a predictor of immunotherapy response in breast cancer. Oncotarget. 2021;12(5):394–400.
   PubMedGoogle Scholar
• Mazzarella L, Duso BA, Trapani D, et al. The evolving landscape of ‘next-generation’ immune checkpoint inhibitors: a review [Internet]. Eur J Cancer. 2019;117:14–31.
   PubMed Web of Science ®Google Scholar
• Maruhashi T, Sugiura D, Okazaki I, et al. LAG-3: from molecular functions to clinical applications. J Immunother Cancer. 2020;8(2):e001014.
   PubMed Web of Science ®Google Scholar
• Woo S-R, Turnis ME, Goldberg MV, et al. Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res. 2012;72(4):917–927.
   PubMed Web of Science ®Google Scholar
• Burugu S, Gao D, Leung S, et al. LAG-3+ tumor infiltrating lymphocytes in breast cancer: clinical correlates and association with PD-1/PD-L1+ tumors. Ann Oncol. 2017;28(12):2977–2984.
   PubMed Web of Science ®Google Scholar
• Anderson AC, Joller N, Kuchroo VK. Lag-3, Tim-3, and TIGIT: co-inhibitory receptors with specialized functions in immune regulation. Immunity. 2016;44(5):989–1004.
   PubMed Web of Science ®Google Scholar
• Burugu S, Gao D, Leung S, et al. TIM-3 expression in breast cancer. Oncoimmunology. 2018;7(11):e1502128.
   PubMed Web of Science ®Google Scholar
• Johnston RJ, Comps-Agrar L, Hackney J, et al. The immunoreceptor TIGIT regulates antitumor and antiviral CD8 + T cell effector function. Cancer Cell. 2014;26(6):923–937.
   PubMed Web of Science ®Google Scholar
• Mehta N, Maddineni S, Kelly RL, et al. An engineered antibody binds a distinct epitope and is a potent inhibitor of murine and human VISTA. Sci Rep. 2020;10(1):15171.
   PubMed Web of Science ®Google Scholar
• Huang X, Zhang X, Li E, et al. VISTA: an immune regulatory protein checking tumor and immune cells in cancer immunotherapy. J Hematol Oncol. 2020;13(1):83.
   PubMed Web of Science ®Google Scholar
• Liu S, Liang J, Liu Z, Zhang C, Wang Y, Watson AH, Zhou C, Zhang F, Wu K, Zhang F, Lu Y, Wang X. The Role of CD276 in Cancers. Front Oncol. 2021 Mar 26;11:654684. doi:https://doi.org/10.3389/fonc.2021.654684.PMID: 33842369; PMCID: PMC8032984
   Google Scholar
• Picarda E, Ohaegbulam KC, Zang X. Molecular pathways: targeting B7-H3 (CD276) for human cancer immunotherapy. Clin Cancer Res. 2016;22(14):3425–3431.
   PubMed Web of Science ®Google Scholar
• Tabana Y, Okoye IS, Siraki A, et al. Tackling immune targets for breast cancer: beyond PD-1/PD-L1 axis. Front Oncol. 2021;11. DOI:https://doi.org/10.3389/fonc.2021.628138.
   Google Scholar
• Aspeslagh S, Postel-Vinay S, Rusakiewicz S, et al. Rationale for anti-OX40 cancer immunotherapy. Eur J Cancer. 2016;52:50–66.
   PubMed Web of Science ®Google Scholar
• Buzzatti G, Dellepiane C, Del Mastro L. New emerging targets in cancer immunotherapy: the role of GITR. ESMO Open. 2019;4:e000738.
   Web of Science ®Google Scholar
• Cohen AD, Schaer DA, Liu C, et al. Agonist Anti-GITR monoclonal antibody induces melanoma tumor immunity in mice by altering regulatory T cell stability and intra-tumor accumulation. PLoS One. 2010;5(5):e10436.
   PubMed Web of Science ®Google Scholar
• Compte M, Harwood SL, Erce-Llamazares A, et al. An Fc-free EGFR-specific 4-1BB-agonistic trimerbody displays broad anti-tumor activity in humanized murine cancer models without toxicity. Clin Cancer Res Clincanres. 2021;4625:2020.
   Google Scholar
• Djureinovic D, Wang M, Kluger HM. Agonistic CD40 antibodies in cancer treatment. Cancers (Basel). 2021;13(6):1302.
   PubMed Web of Science ®Google Scholar
• Fan X, Quezada SA, Sepulveda MA, et al. Engagement of the ICOS pathway markedly enhances efficacy of CTLA-4 blockade in cancer immunotherapy. J Exp Med. 2014;211(4):715–725.
   PubMed Web of Science ®Google Scholar
• Marin-Acevedo JA, Kimbrough EOMO, Lou Y. Next generation of immune checkpoint inhibitors and beyond. J Hematol Oncol. 2021;14:45.
   Web of Science ®Google Scholar
• Hong DS, Schoffski P, Calvo A, et al. Phase I/II study of LAG525 ± spartalizumab (PDR001) in patients (pts) with advanced malignancies. J Clin Oncol. 2018;36(15_suppl): 3012–3012. DOI:https://doi.org/10.1200/JCO.2018.36.15_suppl.3012.
   Google Scholar
• Wildiers H, Armstrong A, Cuypere E, et al. Primary efficacy results from AIPAC: a double-blinded, placebo controlled, randomized multinational phase IIb trial comparing weekly paclitaxel plus eftilagimod alpha (soluble LAG-3 protein) vs. weekly paclitaxel plus placebo in HR-positive metastatic bre. SABCS2020.
   Google Scholar
• Luke JJ, Patel MR, Hamilton EP, et al. A phase I, first-in-human, open-label, dose-escalation study of MGD013, a bispecific DART molecule binding PD-1 and LAG-3, in patients with unresectable or metastatic neoplasms. J Clin Oncol. 2020;38(15_suppl): 3004–3004. DOI:https://doi.org/10.1200/JCO.2020.38.15_suppl.3004.
   Google Scholar
• Lipson EJ, Tawbi -HA-H, Schadendorf D, et al. Relatlimab (RELA) plus nivolumab (NIVO) versus NIVO in first-line advanced melanoma: primary phase III results from RELATIVITY-047 (CA224-047). J Clin Oncol. 2021;39(15_suppl): 9503–9503. DOI:https://doi.org/10.1200/JCO.2021.39.15_suppl.9503.
   Google Scholar
• Curigliano G, Gelderblom H, Mach N, et al. Abstract CT183: phase (Ph) I/II study of MBG453± spartalizumab (PDR001) in patients (pts) with advanced malignancies, in Clinical Trials. Am Assoc Cancer Res. 2019;CT183–CT183.
   Google Scholar
• Yap TA, Burris HA, Kummar S, et al. ICONIC: biologic and clinical activity of first in class ICOS agonist antibody JTX-2011 ± nivolumab (nivo) in patients (pts) with advanced cancers. J Clin Oncol. 2018;36(15_suppl): 3000–3000. DOI:https://doi.org/10.1200/JCO.2018.36.15_suppl.3000.
   Google Scholar
• Marabelle A, Tselikas L, De Baere T, et al. Intratumoral immunotherapy: using the tumor as the remedy. Ann Oncol. 2017;28:xii33–xii43.
   PubMed Web of Science ®Google Scholar
• Zanker DJ, Spurling AJ, Brockwell NK, et al. Intratumoral administration of the Toll‐like receptor 7/8 agonist 3M‐052 enhances interferon‐driven tumor immunogenicity and suppresses metastatic spread in preclinical triple‐negative breast cancer. Clin Transl Immunol. 2020;9(9). DOI:https://doi.org/10.1002/cti2.1177.
   Google Scholar
• Adams S, Kozhaya L, Martiniuk F, et al. Topical TLR7 agonist imiquimod can induce immune-mediated rejection of skin metastases in patients with breast cancer. Clin Cancer Res. 2012;18(24):6748–6757.
   PubMed Web of Science ®Google Scholar
• Curigliano G, Jimenez MM, Shimizu T, et al. CT103 - Phase I study of LHC165 ± spartalizumab (PDR001) in patients (pts) with advanced solid tumors. AACR Annu Meet. 2021.
   Google Scholar
• Ott PA, Hodi FS. Talimogene Laherparepvec for the treatment of advanced melanoma. Clin Cancer Res. 2016;22(13):3127–3131.
   PubMed Web of Science ®Google Scholar
• Soliman H, Hogue D, Han H, et al. A phase i trial of talimogene laherparepvec in combination with neoadjuvant chemotherapy for the treatment of nonmetastatic triple-negative breast cancer. Clin Cancer Res. 2021;27(4):1012–1018.
   PubMed Web of Science ®Google Scholar
• Peoples GE, Holmes JP, Hueman MT, et al. Combined clinical trial results of a HER2/ neu (E75) vaccine for the prevention of recurrence in high-risk breast cancer patients: u.S. military cancer institute clinical trials group study I-01 and I-02. Clin Cancer Res. 2008;14(3):797–803.
   PubMed Web of Science ®Google Scholar
• Mittendorf EAA, Clifton GTT, Holmes JPP, et al. Final report of the phase I/II clinical trial of the E75 (nelipepimut-S) vaccine with booster inoculations to prevent disease recurrence in high-risk breast cancer patients. Ann Oncol. 2014;25(9):1735–1742.
   PubMed Web of Science ®Google Scholar
• Mittendorf EA, Lu B, Melisko M, et al. Efficacy and safety analysis of nelipepimut-S vaccine to prevent breast cancer recurrence: a randomized, multicenter, phase III clinical trial. Clin Cancer Res. 2019;25(14):4248–4254.
   PubMed Web of Science ®Google Scholar
• Dillon PM, Brenin CM, Slingluff Jr CL. Evaluating nelipepimut-s in the treatment of breast cancer: a short report on the emerging data. Breast Cancer Targets Ther. 2020;12: 69–75.
   PubMed Web of Science ®Google Scholar
• Chick RC, Clifton GT, Hale DF, et al. Subgroup analysis of nelipepimut-S plus GM-CSF combined with trastuzumab versus trastuzumab alone to prevent recurrences in patients with high-risk, HER2 low-expressing breast cancer. Clin Immunol. 2021;225:108679.
   PubMed Web of Science ®Google Scholar
• Bonehill A, Tuyaerts S, Van Nuffel AM, et al. Enhancing the T-cell stimulatory capacity of human dendritic cells by co-electroporation with CD40L, CD70 and constitutively active TLR4 encoding mRNA. Mol Ther. 2008;16(6):1170–1180.
   PubMed Web of Science ®Google Scholar
• Wilgenhof S, Corthals J, Heirman C, et al. Phase II study of autologous monocyte-derived mRNA electroporated dendritic cells (TriMixDC-MEL) plus ipilimumab in patients with pretreated advanced melanoma. J Clin Oncol. 2016;34(12):1330–1338.
   PubMed Web of Science ®Google Scholar
• Venetis K, Invernizzi M, Sajjadi E, et al. Cellular immunotherapy in breast cancer: the quest for consistent biomarkers. Cancer Treat Rev. 2020;90:102089.
   PubMed Web of Science ®Google Scholar
• Chen L, Zhimin S, Wang Z, et al. Combination of famitinib with camrelizumab plus nab-paclitaxel as first-line treatment for patients with immunomodulatory advanced triple-negative breast cancer (FUTURE-C-PLUS): a prospective, single-arm, phase 2 study. J Clin Oncol. 2021;39(15_suppl): 1007–1007. DOI:https://doi.org/10.1200/JCO.2021.39.15_suppl.1007.
   Google Scholar
• Schmid P, Im S-A, Armstrong A, et al. BEGONIA: phase 1b/2 study of durvalumab (D) combinations in locally advanced/metastatic triple-negative breast cancer (TNBC)—Initial results from arm 1, d+paclitaxel (P), and arm 6, d+trastuzumab deruxtecan (T-DXd). J Clin Oncol. 2021;39(15_suppl): 1023–1023. DOI:https://doi.org/10.1200/JCO.2021.39.15_suppl.1023.
   Google Scholar
• Tarantino P, Marra A, Gandini S, et al. Association between baseline tumour burden and outcome in patients with cancer treated with next-generation immunoncology agents. Eur J Cancer. 2020;139:92–98.
   PubMed Web of Science ®Google Scholar
• Ignatiadis M, Sledge GW, Jeffrey SS. Liquid biopsy enters the clinic — implementation issues and future challenges. Nat Rev Clin Oncol. 2021;18(5):297–312.
   PubMed Web of Science ®Google Scholar